Laboratory tests will include total blood counts, liver panel, fetoprotein, HBeAg, anti-HBe antibody status and HBV DNA levels
Laboratory tests will include total blood counts, liver panel, fetoprotein, HBeAg, anti-HBe antibody status and HBV DNA levels. to start treatment, with what medication and for how long? There is now enough evidence to support that hepatitis B patients should be considered for treatment Rabbit polyclonal to TP73 if they show persistently elevated abnormal aminotransferase levels in the last 6 mo, checked on at least three separate occasions, and a serum hepatitis B computer virus DNA level of > 2000 IU/mL. Therapeutic agents that were approved by Pure Food and Drug Administration are now available in many developing countries. These include standard interferon (INF)-, pegylated INF-, lamivudine, adefovir, entecavir and telbivudine. Drug resistance has emerged as a major challenge in the management of patients with CHB. The role of the universal vaccination program for effective control of hepatitis B cannot be emphasized enough. Keywords:Hepatitis B, Management, Developing countries, Hepatitis B surface antigen, Hepatitis B computer virus DNA, Vaccination == INTRODUCTION == Hepatitis B is the leading cause of chronic viral hepatitis across the world. More than two billion people worldwide show serological evidence of exposure to this virus, comprising about one third of the global populace and approximately 350-400 million carry the chronic infection[1,2]. Chronic hepatitis B (CHB) contamination leads to cirrhosis and is still a major cause of hepatocellular carcinoma in many parts of the developing world[3,4]. For children under 1 year, the risk of chronic contamination is usually 90%[5]. About 25% of adults who become chronically infected during childhood pass away prematurely from liver cancer or cirrhosis, caused by its chronic contamination[2]. But if adults are infected by hepatitis B computer virus (HBV) after child years, 90% will eventually fully recover. Hepatitis B causes an estimated one million deaths per year worldwide[6]. It is estimated that 5 % to 15% of the population are chronic carriers of hepatitis B in developing countries, whereas in North America and Western Europe only 1% of the population is chronically infected. Chronic HBV contamination is highly prevalent in sub-Saharan Africa, Southeast Asia, the Eastern Mediterranean region, the Amazon basin and the Caribbean[7-9]. Hepatocellular carcinoma seems to be more common in Africa and Asia than in other parts of the world due to Hepatitis B contamination. Many developing countries often face significant health and hygiene difficulties that predispose to the transmission of hepatitis viruses. Most hepatitis B patients present with advanced disease. Contributing factors leading to late presentation include ignorance, poverty, lack of easy accessibility to healthcare centers, lack of trained staff and diagnostic facilities, un-affordability of expensive drugs and consultations from quacks and traditional healers that misguide patients. == TRANSMISSION == Perinatal transmission is believed to be the most important mode in regions of developing world with high and intermediate HBV prevalence rates[10]. Transmission occurs from mother to child or from child to child, mainly through cuts, bites, scrapes and U-93631 scratches. Although most infections in the developing world occur in child years and early adulthood, a significant proportion of non-immune adults remain at risk to healthcare-acquired infections. HBV remains a major nosocomial pathogen in many hospitals[11]. Transmission may occur due to unsafe injections, blood transfusions and lack of awareness of contamination control[12,13]. Healthcare providers may be unaware of the natural history of hepatic cellular cancer (HCC) and the need for continuous lifetime monitoring of HBV contamination status[4]. Sexual contact also accounts for some HBV transmission. == Phases of contamination == The natural history of CHB has been defined into different phases: the immune tolerant phase, the immune reactive phase and the inactive carrier phase and hepatitis B e antigen (HBeAg) unfavorable disease[14-17]. In the immune tolerant phase, HBeAg is usually positive, HBV DNA is usually elevated, abnormal aminotransferase (ALT) U-93631 is usually normal and liver inflammation is usually absent or minimal. The immune reactive phase is characterized by ALT elevation, HBV DNA levels>2000 IU/mL and active liver inflammation and fibrosis of various degrees. A more vigorous cytotoxic T-cell response may occur eventually, resulting in seroconversion from HBeAg to anti-HBe during this phase. After seroconversion, most patients go into the inactive hepatitis B carrier phase characterized by normal ALT levels, low levels of HBV DNA (<2000 IU copies/mL) and improvement of liver inflammation and fibrosis over time, provided they remain in the inactive hepatitis B phase. These patients may move from your U-93631 inactive hepatitis phase back to the immune reactive phase, either by going through a reversion from anti-HBe to HBeAg or having.